Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Amidotricoic Acid
2. Amidotrizoate, Meglumine
3. Angiografin
4. Diatrizoate Methylglucamine
5. Diatrizoate, Meglumine
6. Diatrizoate, Methylglucamine
7. Diatrizoic Acid Methylglucamine
8. Gastrograffin
9. Gastrografin
10. Gastrographin
11. Ioxeol
12. Meglumine Amidotrizoate
13. Meglumine Diatrizoate
14. Meglumine, Diatrizoate
15. Methylglucamine Diatrizoate
16. Methylglucamine, Diatrizoate
17. Methylglucamine, Diatrizoic Acid
18. Reno 60
19. Reno M Dip
20. Reno M-dip
21. Reno Mdip
22. Renograffin
23. Renografin
24. Renografin M 76
25. Renografin M-76
26. Renografin M76
27. Sinografin
28. Triombrast
29. Triombrin
30. Urografin
31. Urografin 76
32. Urovist
33. Verografin
1. Meglumine Diatrizoate
2. 131-49-7
3. Meglumine Amidotrizoate
4. Renografin
5. Cardiografin
6. Cystografin
7. Renovist
8. Renocal
9. Angiovist 282
10. Diatrizoate Methylglucamine
11. Reno
12. Urovist Cysto
13. Urovist Cysto Pediatric
14. Urovist Meglumine Diu/ct
15. Meglumine Amidotrizoate Injection
16. Diatrizoate Meglumine [usp]
17. 131-49-7 (meglumine)
18. Diatrizoic Acid Meglumine Salt
19. 3x9mr4n98u
20. Angiografin
21. Urovist
22. 1-deoxy-1-(methylamino)-d-glucitol 3,5-diacetamido-2,4,6-triiodobenzoate (salt)
23. Renurix
24. Unipaque
25. Hypaque Meglumine
26. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 3,5-diacetamido-2,4,6-triiodobenzoate
27. Cystographin Dilute
28. Diatrizoate Meglumine (usp)
29. Reno-m
30. Reno-m-dip
31. Benzoic Acid, 3,5-bis(acetylamino)-2,4,6-triiodo-, Compd. With 1-deoxy-1-(methylamino)-d-glucitol (1:1)
32. Hypaque 60
33. Renograffin M-76
34. Hypaque M 30
35. Hypaque 13.4
36. Reno-30
37. Hypaque-cysto
38. Reno-dip
39. Cystografin Dilute
40. Reno M 60
41. Gastrografin Oral (veterinary)
42. Reno-60
43. Md 60
44. Einecs 205-024-7
45. Unii-3x9mr4n98u
46. Hypaque (tn)
47. Urovist (tn)
48. Reno (tn)
49. 3,5-bis(acetamido)-2,4,6-triiodbenzoesaeure, 1-desoxy-1-methylamino-d-glucit-salz
50. Benzoic Acid, 3,5-diacetamido-2,4,6-triiodo-, Compd. With 1-deoxy-1-(methylamino)-d-glucitol
51. Schembl107036
52. Chembl1200839
53. Dtxsid20897171
54. Hms2234f23
55. Diatrizoate Meglumine [vandf]
56. Meglumine Amidotrizoate [mart.]
57. Glucitol, 1-deoxy-1-(methylamino)-, 3,5-diacetamido-2,4,6-triiodobenzoate (salt), D-
58. Meglumine Amidotrizoate [who-dd]
59. Diatrizoate Meglumine [green Book]
60. Diatrizoate Meglumine [orange Book]
61. Diatrizoic Acid Meglumine Salt [mi]
62. Diatrizoate Meglumine [usp Monograph]
63. Renocal Component Diatrizoate Meglumine
64. Angiovist Component Diatrizoate Meglumine
65. D02015
66. Meglumine Amidotrizoate Injection [jan]
67. Renovist Component Diatrizoate Meglumine
68. Diatrizoate Meglumine Component Of Renocal
69. Gastrovist Component Diatrizoate Meglumine
70. Renografin Component Diatrizoate Meglumine
71. Sinografin Component Diatrizoate Meglumine
72. Diatrizoate Meglumine Component Of Angiovist
73. Diatrizoate Meglumine Component Of Renovist
74. Gastrografin Component Diatrizoate Meglumine
75. Diatrizoate Meglumine Component Of Gastrovist
76. Diatrizoate Meglumine Component Of Renografin
77. Diatrizoate Meglumine Component Of Sinografin
78. Md-gastroview Component Diatrizoate Meglumine
79. Diatrizoate Meglumine Component Of Gastrografin
80. Q27114690
81. Diatrizoate Meglumine Component Of Md-gastroview
Molecular Weight | 809.1 g/mol |
---|---|
Molecular Formula | C18H26I3N3O9 |
Hydrogen Bond Donor Count | 9 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 9 |
Exact Mass | 808.8803 g/mol |
Monoisotopic Mass | 808.8803 g/mol |
Topological Polar Surface Area | 209 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 525 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Cystografin |
Drug Label | Cystografin is a radiopaque contrast agent supplied as a sterile, clear, colorless to pale yellow, mobile or slightly viscous solution. Each mL provides 300 mg diatrizoate meglumine with 0.4 mg edetate disodium as a sequestering agent. Each mL of sol... |
Active Ingredient | Diatrizoate meglumine |
Dosage Form | Solution |
Route | Urethral |
Strength | 30% |
Market Status | Prescription |
Company | Bracco |
2 of 6 | |
---|---|
Drug Name | Cystografin dilute |
Drug Label | Cystografin Dilute (Diatrizoate Meglumine Injection USP 18%) is a radiopaque contrast agent supplied as a sterile, aqueous solution. Each mL provides 180 mg diatrizoate meglumine with 0.4 mg edetate disodium as a sequestering agent. Each mL of soluti... |
Active Ingredient | Diatrizoate meglumine |
Dosage Form | Solution |
Route | Urethral |
Strength | 18% |
Market Status | Prescription |
Company | Bracco |
3 of 6 | |
---|---|
Drug Name | Sinografin |
Drug Label | Sinografin (Diatrizoate Meglumine and lodipamide Meglumine Injection) is a sterile, nonpyrogenic, essentially colorless to pale yellow, aqueous radiopaque contrast medium for intrauterine instillation. Each mL provides 527 mg diatrizoate meglumine an... |
Active Ingredient | Diatrizoate meglumine; iodipamide meglumine |
Dosage Form | Solution |
Route | Intrauterine |
Strength | 26.8%; 52.7% |
Market Status | Prescription |
Company | Bracco |
4 of 6 | |
---|---|
Drug Name | Cystografin |
Drug Label | Cystografin is a radiopaque contrast agent supplied as a sterile, clear, colorless to pale yellow, mobile or slightly viscous solution. Each mL provides 300 mg diatrizoate meglumine with 0.4 mg edetate disodium as a sequestering agent. Each mL of sol... |
Active Ingredient | Diatrizoate meglumine |
Dosage Form | Solution |
Route | Urethral |
Strength | 30% |
Market Status | Prescription |
Company | Bracco |
5 of 6 | |
---|---|
Drug Name | Cystografin dilute |
Drug Label | Cystografin Dilute (Diatrizoate Meglumine Injection USP 18%) is a radiopaque contrast agent supplied as a sterile, aqueous solution. Each mL provides 180 mg diatrizoate meglumine with 0.4 mg edetate disodium as a sequestering agent. Each mL of soluti... |
Active Ingredient | Diatrizoate meglumine |
Dosage Form | Solution |
Route | Urethral |
Strength | 18% |
Market Status | Prescription |
Company | Bracco |
6 of 6 | |
---|---|
Drug Name | Sinografin |
Drug Label | Sinografin (Diatrizoate Meglumine and lodipamide Meglumine Injection) is a sterile, nonpyrogenic, essentially colorless to pale yellow, aqueous radiopaque contrast medium for intrauterine instillation. Each mL provides 527 mg diatrizoate meglumine an... |
Active Ingredient | Diatrizoate meglumine; iodipamide meglumine |
Dosage Form | Solution |
Route | Intrauterine |
Strength | 26.8%; 52.7% |
Market Status | Prescription |
Company | Bracco |
Contrast Media
Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
RLD : No
TE Code :
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM
Brand Name : DIATRIZOATE-60
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 52%;8%
Approval Date : 1983-06-17
Application Number : 88166
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : UROVIST MEGLUMINE DIU/CT
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 30%
Approval Date : 1982-09-23
Application Number : 87739
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : RENO-60
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 60%
Approval Date : 1982-01-01
Application Number : 10040
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : DIATRIZOATE MEGLUMINE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 76%
Approval Date : 1982-01-01
Application Number : 10040
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
Brand Name : CYSTOGRAFIN
Dosage Form : SOLUTION;URETHRAL
Dosage Strength : 30%
Approval Date : 1982-01-01
Application Number : 10040
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code : AA
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM
Brand Name : GASTROGRAFIN
Dosage Form : SOLUTION;ORAL, RECTAL
Dosage Strength : 66%;10%
Approval Date : 1982-01-01
Application Number : 11245
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AA
RLD : Yes
TE Code :
DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE
Brand Name : SINOGRAFIN
Dosage Form : SOLUTION;INTRAUTERINE
Dosage Strength : 52.7%;26.8%
Approval Date : 1982-01-01
Application Number : 11324
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : No
TE Code :
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM
Brand Name : HYPAQUE-76
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 66%;10%
Approval Date : 1982-01-01
Application Number : 86505
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM
Brand Name : MD-76
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 66%;10%
Approval Date : 1982-01-01
Application Number : 87073
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM
Brand Name : MD-60
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 52%;8%
Approval Date : 1982-01-01
Application Number : 87074
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
86
PharmaCompass offers a list of Diatrizoate Meglumine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Diatrizoate Meglumine manufacturer or Diatrizoate Meglumine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Diatrizoate Meglumine manufacturer or Diatrizoate Meglumine supplier.
PharmaCompass also assists you with knowing the Diatrizoate Meglumine API Price utilized in the formulation of products. Diatrizoate Meglumine API Price is not always fixed or binding as the Diatrizoate Meglumine Price is obtained through a variety of data sources. The Diatrizoate Meglumine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A RENOGRAFIN-76 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of RENOGRAFIN-76, including repackagers and relabelers. The FDA regulates RENOGRAFIN-76 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. RENOGRAFIN-76 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of RENOGRAFIN-76 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A RENOGRAFIN-76 supplier is an individual or a company that provides RENOGRAFIN-76 active pharmaceutical ingredient (API) or RENOGRAFIN-76 finished formulations upon request. The RENOGRAFIN-76 suppliers may include RENOGRAFIN-76 API manufacturers, exporters, distributors and traders.
click here to find a list of RENOGRAFIN-76 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A RENOGRAFIN-76 DMF (Drug Master File) is a document detailing the whole manufacturing process of RENOGRAFIN-76 active pharmaceutical ingredient (API) in detail. Different forms of RENOGRAFIN-76 DMFs exist exist since differing nations have different regulations, such as RENOGRAFIN-76 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A RENOGRAFIN-76 DMF submitted to regulatory agencies in the US is known as a USDMF. RENOGRAFIN-76 USDMF includes data on RENOGRAFIN-76's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The RENOGRAFIN-76 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of RENOGRAFIN-76 suppliers with USDMF on PharmaCompass.
A RENOGRAFIN-76 written confirmation (RENOGRAFIN-76 WC) is an official document issued by a regulatory agency to a RENOGRAFIN-76 manufacturer, verifying that the manufacturing facility of a RENOGRAFIN-76 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting RENOGRAFIN-76 APIs or RENOGRAFIN-76 finished pharmaceutical products to another nation, regulatory agencies frequently require a RENOGRAFIN-76 WC (written confirmation) as part of the regulatory process.
click here to find a list of RENOGRAFIN-76 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing RENOGRAFIN-76 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for RENOGRAFIN-76 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture RENOGRAFIN-76 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain RENOGRAFIN-76 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a RENOGRAFIN-76 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of RENOGRAFIN-76 suppliers with NDC on PharmaCompass.
RENOGRAFIN-76 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of RENOGRAFIN-76 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right RENOGRAFIN-76 GMP manufacturer or RENOGRAFIN-76 GMP API supplier for your needs.
A RENOGRAFIN-76 CoA (Certificate of Analysis) is a formal document that attests to RENOGRAFIN-76's compliance with RENOGRAFIN-76 specifications and serves as a tool for batch-level quality control.
RENOGRAFIN-76 CoA mostly includes findings from lab analyses of a specific batch. For each RENOGRAFIN-76 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
RENOGRAFIN-76 may be tested according to a variety of international standards, such as European Pharmacopoeia (RENOGRAFIN-76 EP), RENOGRAFIN-76 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (RENOGRAFIN-76 USP).